CenterBook Partners LP Acquires 589,158 Shares of Indivior PLC (NASDAQ:INDV)

CenterBook Partners LP raised its holdings in Indivior PLC (NASDAQ:INDV - Free Report) by 105.5% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 1,147,841 shares of the company's stock after acquiring an additional 589,158 shares during the quarter. Indivior comprises 0.9% of CenterBook Partners LP's portfolio, making the stock its 21st largest position. CenterBook Partners LP owned approximately 0.83% of Indivior worth $14,268,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also added to or reduced their stakes in INDV. Mirae Asset Global Investments Co. Ltd. acquired a new position in Indivior in the fourth quarter valued at about $56,000. Stifel Financial Corp acquired a new position in Indivior during the 3rd quarter worth approximately $100,000. Rathbones Group PLC increased its stake in Indivior by 11.6% in the 4th quarter. Rathbones Group PLC now owns 14,284 shares of the company's stock valued at $183,000 after buying an additional 1,483 shares during the last quarter. Jane Street Group LLC acquired a new stake in shares of Indivior in the third quarter valued at about $180,000. Finally, China Universal Asset Management Co. Ltd. bought a new position in Indivior during the fourth quarter worth about $359,000. Institutional investors own 60.33% of the company's stock.

Indivior Trading Up 1.3 %

Indivior stock traded up $0.12 during mid-day trading on Monday, reaching $9.23. The company had a trading volume of 291,090 shares, compared to its average volume of 928,575. The business has a fifty day simple moving average of $9.61 and a 200 day simple moving average of $10.36. Indivior PLC has a fifty-two week low of $7.33 and a fifty-two week high of $20.10. The company has a market cap of $1.27 billion, a P/E ratio of -26.37 and a beta of 0.93.

Indivior (NASDAQ:INDV - Get Free Report) last announced its quarterly earnings results on Thursday, February 20th. The company reported $0.32 earnings per share (EPS) for the quarter, meeting the consensus estimate of $0.32. The firm had revenue of $298.00 million during the quarter, compared to analysts' expectations of $262.35 million. Indivior had a negative net margin of 3.96% and a negative return on equity of 241.73%. Research analysts forecast that Indivior PLC will post 1.22 EPS for the current year.

Analyst Upgrades and Downgrades

Several brokerages have issued reports on INDV. Piper Sandler cut their price objective on shares of Indivior from $16.00 to $13.00 and set an "overweight" rating for the company in a research report on Thursday, March 6th. RODMAN&RENSHAW upgraded shares of Indivior to a "strong-buy" rating in a research report on Tuesday, January 28th. Finally, Rodman & Renshaw assumed coverage on Indivior in a report on Tuesday, January 28th. They issued a "buy" rating and a $16.00 price objective for the company.

Indivior Profile

Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders in the United States, the United Kingdom, and internationally. The company develops medicines to treat substance use disorders, serious mental illnesses, and opioid overdose.